Literature DB >> 11307091

Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators.

T A Sohn1, C J Yeo, J L Cameron, L Koniaris, S Kaushal, R A Abrams, P K Sauter, J Coleman, R H Hruban, K D Lillemoe.   

Abstract

This large-volume, single-institution review examines factors influencing long-term survival after resection in patients with adenocarcinoma of the head, neck, uncinate process, body, or tail of the pancreas. Between January 1984 and July 1999 inclusive, 616 patients with adenocarcinoma of the pancreas underwent surgical resection. A retrospective analysis of a prospectively collected database was performed. Both univariate and multivariate models were used to determine the factors influencing survival. Of the 616 patients, 526 (85%) underwent pancreaticoduodenectomy for adenocarcinoma of the head, neck, or uncinate process of the pancreas, 52 (9%) underwent distal pancreatectomy for adenocarcinoma of the body or tail, and 38 (6%) underwent total pancreatectomy for adenocarcinoma extensively involving the gland. The mean age of the patients was 64.3 years, with 54% being male and 91% being white. The overall perioperative mortality rate was 2.3%, whereas the incidence of postoperative complications was 30%. The median postoperative length of stay was 11 days. The mean tumor diameter was 3.2 cm, with 72% of patients having positive lymph nodes, 30% having positive resection margins, and 36% having poorly differentiated tumors. Patients undergoing distal pancreatectomy for left-sided lesions had larger tumors (4.7 vs. 3.1 cm, P < 0.0001), but fewer node-positive resections (59% vs. 73%, P = 0.03) and fewer poorly differentiated tumors (29% vs. 36%, P < 0.001), as compared to those undergoing pancreaticoduodenectomy for right-sided lesions. The overall survival of the entire cohort was 63% at 1 year and 17% at 5 years, with a median survival of 17 months. For right-sided lesions the 1- and 5-year survival rates were 64% and 17%, respectively, compared to 50% and 15% for left-sided lesions. Factors shown to have favorable independent prognostic significance by multivariate analysis were negative resection margins (hazard ratio [HR] = 0.64, confidence interval [CI] = 0.50 to 0.82, P = 0.0004), tumor diameter less than 3 cm (HR = 0.72, CI = 0.57 to 0.90, P = 0.004), estimated blood loss less than 750 ml (HR = 0.75, CI = 0.58 to 0.96, P = 0.02), well/moderate tumor differentiation (HR = 0.71, CI = 0.56 to 0.90, P = 0.005), and postoperative chemoradiation (HR = 0.50, CI = 0.39 to 0.64, P < 0.0001). Tumor location in head, neck, or uncinate process approached significance in the final multivariate model (HR = 0.60, CI = 0.35 to 1.0, P = 0.06). Pancreatic resection remains the only hope for long-term survival in patients with adenocarcinoma of the pancreas. Completeness of resection and tumor characteristics including tumor size and degree of differentiation are important independent prognostic indicators. Adjuvant chemoradiation is a strong predictor of outcome and likely decreases the independent significance of tumor location and nodal status.

Entities:  

Mesh:

Year:  2000        PMID: 11307091     DOI: 10.1016/s1091-255x(00)80105-5

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  44 in total

1.  Surgical curability and prognosis for standard versus extended resection for T1 carcinoma of the pancreas.

Authors:  K Satake; H Nishiwaki; H Yokomatsu; Y Kawazoe; K Kim; A Haku; K Umeyama; I Miyazaki
Journal:  Surg Gynecol Obstet       Date:  1992-09

2.  The advantages of bypass operations over radical pancreatoduodenectomy in the treatment of pancreatic carcinoma.

Authors:  G Crile
Journal:  Surg Gynecol Obstet       Date:  1970-06

3.  Pancreatic cancer cell DNA content correlates with long-term survival after pancreatoduodenectomy.

Authors:  D C Allison; K K Bose; R H Hruban; S Piantadosi; W C Dooley; J K Boitnott; J L Cameron
Journal:  Ann Surg       Date:  1991-12       Impact factor: 12.969

4.  p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions.

Authors:  M S Redston; C Caldas; A B Seymour; R H Hruban; L da Costa; C J Yeo; S E Kern
Journal:  Cancer Res       Date:  1994-06-01       Impact factor: 12.701

5.  Identification of K-ras mutations in pancreatic juice in the early diagnosis of pancreatic cancer.

Authors:  P Berthélemy; M Bouisson; J Escourrou; N Vaysse; J L Rumeau; L Pradayrol
Journal:  Ann Intern Med       Date:  1995-08-01       Impact factor: 25.391

6.  Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas: a multicenter, prospective, randomized study. Lymphadenectomy Study Group.

Authors:  S Pedrazzoli; V DiCarlo; R Dionigi; F Mosca; P Pederzoli; C Pasquali; G Klöppel; K Dhaene; F Michelassi
Journal:  Ann Surg       Date:  1998-10       Impact factor: 12.969

7.  Early evaluation of abdominal/hepatic irradiation and 5-fluorouracil/leucovorin infusion after pancreaticoduodenectomy.

Authors:  M A Carducci; R A Abrams; C J Yeo; R H Hruban; M L Zahurak; J L Cameron; L B Grochow
Journal:  Int J Radiat Oncol Biol Phys       Date:  1996-04-01       Impact factor: 7.038

8.  Periampullary adenocarcinoma: analysis of 5-year survivors.

Authors:  C J Yeo; T A Sohn; J L Cameron; R H Hruban; K D Lillemoe; H A Pitt
Journal:  Ann Surg       Date:  1998-06       Impact factor: 12.969

Review 9.  Pancreatoduodenectomy with pyloric preservation for carcinoma of the pancreas: a cautionary note.

Authors:  K W Sharp; C B Ross; S A Halter; J G Morrison; W O Richards; L F Williams; J L Sawyers
Journal:  Surgery       Date:  1989-05       Impact factor: 3.982

10.  Adenocarcinoma of the body and tail of the pancreas: is there room for adjuvant radiotherapy?

Authors:  R Coquard; L Ayzac; P Romestaing; J M Ardiet; I Sentenac; F N Gilly; G Braillon; J P Gérard
Journal:  Tumori       Date:  1997 Jul-Aug
View more
  447 in total

Review 1.  Recent advances in the surgical treatment of pancreatic cancer.

Authors:  A Shankar; R C Russell
Journal:  World J Gastroenterol       Date:  2001-10       Impact factor: 5.742

Review 2.  Current and future strategies for combined-modality therapy in pancreatic cancer.

Authors:  Andrew H Ko; Margaret A Tempero
Journal:  Curr Oncol Rep       Date:  2002-05       Impact factor: 5.075

3.  The role of MRI in pancreatic cancer.

Authors:  Philip A Robinson
Journal:  Eur Radiol       Date:  2001-10-16       Impact factor: 5.315

Review 4.  Adjuvant therapy for pancreatic adenocarcinoma.

Authors:  R A Abrams
Journal:  J Gastrointest Surg       Date:  2001 Jan-Feb       Impact factor: 3.452

5.  [Distal pancreatectomy with splenectomy and en bloc resection of the celiac trunk for locally advanced cancer of the pancreatic body with infiltration of the celiac trunk].

Authors:  Andreas Andreou; Matthias Glanemann; Olaf Guckelberger; Timm Denecke; Christian Grieser; Petr Podrabsky; Peter Neuhaus
Journal:  Med Klin (Munich)       Date:  2010-04

6.  Peritoneal metastasis from pancreatic cancer treated with pressurized intraperitoneal aerosol chemotherapy (PIPAC).

Authors:  Martin Graversen; Sönke Detlefsen; Jon Kroll Bjerregaard; Per Pfeiffer; Michael Bau Mortensen
Journal:  Clin Exp Metastasis       Date:  2017-05-17       Impact factor: 5.150

Review 7.  Re-adapting T cells for cancer therapy: from mouse models to clinical trials.

Authors:  Ingunn M Stromnes; Thomas M Schmitt; Aude G Chapuis; Sunil R Hingorani; Philip D Greenberg
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

8.  Pyruvate Kinase Muscle Isoenzyme 2 (PKM2) Expression Is Associated with Overall Survival in Pancreatic Ductal Adenocarcinoma.

Authors:  Natalie A Lockney; Manchao Zhang; Yanzhen Lu; Sabrina C Sopha; M Kay Washington; Nipun Merchant; Zhiguo Zhao; Yu Shyr; A Bapsi Chakravarthy; Fen Xia
Journal:  J Gastrointest Cancer       Date:  2015-12

Review 9.  Survival after surgical management of pancreatic adenocarcinoma: does curative and radical surgery truly exist?

Authors:  H G Smeenk; T C K Tran; J Erdmann; C H J van Eijck; J Jeekel
Journal:  Langenbecks Arch Surg       Date:  2004-05-14       Impact factor: 3.445

10.  Early hospital readmission for gastrointestinal-related complications predicts long-term mortality after pancreatectomy.

Authors:  Caitlin W Hicks; Jeffrey J Tosoian; Rebecca Craig-Schapiro; Vicente Valero; John L Cameron; Frederic E Eckhauser; Kenzo Hirose; Martin A Makary; Timothy M Pawlik; Nita Ahuja; Matthew J Weiss; Christopher L Wolfgang
Journal:  Am J Surg       Date:  2015-06-29       Impact factor: 2.565

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.